Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CRISPR Therapeutics AG's share price for the quarter that ended in Dec. 2023 was $62.6. CRISPR Therapeutics AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 80.0 Mil. Therefore, CRISPR Therapeutics AG's market cap for the quarter that ended in Dec. 2023 was $5,010.8 Mil.
CRISPR Therapeutics AG's quarterly market cap
declined
from Jun. 2023 ($4,456.0 Mil) to Sep. 2023 ($3,605.2 Mil) but then
increased
from Sep. 2023 ($3,605.2 Mil) to Dec. 2023 ($5,010.8 Mil).
CRISPR Therapeutics AG's annual market cap
declined
from Dec. 2021 ($5,834.3 Mil) to Dec. 2022 ($3,191.5 Mil) but then
increased
from Dec. 2022 ($3,191.5 Mil) to Dec. 2023 ($5,010.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CRISPR Therapeutics AG's Enterprise Value for Today is $3,310.3 Mil.
CRISPR Therapeutics AG Market Cap Historical Data
The historical data trend for CRISPR Therapeutics AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
CRISPR Therapeutics AG Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Market Cap
3,702.34
11,317.10
5,834.31
3,191.53
5,010.78
CRISPR Therapeutics AG Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Market Cap
3,191.53
3,567.01
4,455.97
3,605.18
5,010.78
Competitive Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Market Cap Distribution
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Market Cap distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Market Cap falls into.
CRISPR Therapeutics AG Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CRISPR Therapeutics AG's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (NAS:CRSP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CRISPR Therapeutics AG Market Cap Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your 